JP2022536854A5 - - Google Patents
Info
- Publication number
- JP2022536854A5 JP2022536854A5 JP2021575320A JP2021575320A JP2022536854A5 JP 2022536854 A5 JP2022536854 A5 JP 2022536854A5 JP 2021575320 A JP2021575320 A JP 2021575320A JP 2021575320 A JP2021575320 A JP 2021575320A JP 2022536854 A5 JP2022536854 A5 JP 2022536854A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863153P | 2019-06-18 | 2019-06-18 | |
| US62/863,153 | 2019-06-18 | ||
| US201962907375P | 2019-09-27 | 2019-09-27 | |
| US62/907,375 | 2019-09-27 | ||
| PCT/US2020/038557 WO2020257536A1 (en) | 2019-06-18 | 2020-06-18 | Patient selection for enhancement of anti-tumor immunity in cancer patients |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022536854A JP2022536854A (ja) | 2022-08-19 |
| JPWO2020257536A5 JPWO2020257536A5 (https=) | 2023-06-27 |
| JP2022536854A5 true JP2022536854A5 (https=) | 2023-06-27 |
| JP7812232B2 JP7812232B2 (ja) | 2026-02-09 |
Family
ID=74040931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575320A Active JP7812232B2 (ja) | 2019-06-18 | 2020-06-18 | 癌患者における抗腫瘍免疫の増強のための患者選択 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220175787A1 (https=) |
| EP (1) | EP3986410A4 (https=) |
| JP (1) | JP7812232B2 (https=) |
| KR (1) | KR20220024540A (https=) |
| CN (1) | CN114222577A (https=) |
| AU (1) | AU2020296087A1 (https=) |
| CA (1) | CA3143339A1 (https=) |
| TW (1) | TW202114684A (https=) |
| WO (1) | WO2020257536A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2968290T3 (da) * | 2013-03-15 | 2019-11-25 | G1 Therapeutics Inc | Transient beskyttelse af normale celler under kemoterapi |
| IL303038B2 (en) | 2016-12-05 | 2024-08-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| ES3048084T3 (en) | 2020-05-19 | 2025-12-09 | Pharmacosmos Holding As | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| WO2022258002A1 (zh) * | 2021-06-10 | 2022-12-15 | 上海岸阔医药科技有限公司 | 治疗化疗相关的胃肠道副作用的化合物和方法 |
| CN118215481A (zh) * | 2021-07-01 | 2024-06-18 | 海南先声再明医药股份有限公司 | 晚期和/或转移性Trop-2过表达癌症患者的联合治疗 |
| WO2023064913A1 (en) * | 2021-10-14 | 2023-04-20 | Wisconsin Alumni Research Foundation | K17 as a biomarker for tumor response to immunotherapy |
| CN115019880B (zh) * | 2022-05-05 | 2024-01-09 | 中山大学附属第一医院 | 一种肝癌预后模型及其构建方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102051881B1 (ko) | 2010-10-25 | 2019-12-04 | 쥐원 쎄라퓨틱스, 인크. | Cdk 억제제 |
| EP2976642A4 (en) | 2013-03-15 | 2016-09-21 | Harvard College | METHOD AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR RECORDING OF A TARGET UNIT |
| DK2968290T3 (da) * | 2013-03-15 | 2019-11-25 | G1 Therapeutics Inc | Transient beskyttelse af normale celler under kemoterapi |
| WO2016126889A1 (en) * | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
| AU2017359333B2 (en) * | 2016-11-08 | 2024-03-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of modulating anti-tumor immunity |
| IL303038B2 (en) * | 2016-12-05 | 2024-08-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| WO2018156812A1 (en) * | 2017-02-22 | 2018-08-30 | G1 Therapeutics, Inc. | Treatment of egfr-driven cancer with fewer side effects |
| WO2019108589A1 (en) * | 2017-11-30 | 2019-06-06 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating cancer |
| US10122265B1 (en) | 2018-01-03 | 2018-11-06 | Intel Corporation | Reducing electromagnetic interference in switching regulators |
| TW202327610A (zh) * | 2021-08-30 | 2023-07-16 | 美商G1治療公司 | 具有檢查點抑制劑抗性或抗性易感性之晚期性/轉移性癌症之改良治療 |
-
2020
- 2020-06-18 EP EP20825571.1A patent/EP3986410A4/en active Pending
- 2020-06-18 CN CN202080056941.0A patent/CN114222577A/zh active Pending
- 2020-06-18 AU AU2020296087A patent/AU2020296087A1/en not_active Abandoned
- 2020-06-18 KR KR1020227001251A patent/KR20220024540A/ko not_active Ceased
- 2020-06-18 JP JP2021575320A patent/JP7812232B2/ja active Active
- 2020-06-18 WO PCT/US2020/038557 patent/WO2020257536A1/en not_active Ceased
- 2020-06-18 TW TW109120659A patent/TW202114684A/zh unknown
- 2020-06-18 CA CA3143339A patent/CA3143339A1/en active Pending
-
2021
- 2021-12-17 US US17/554,940 patent/US20220175787A1/en active Pending